Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Emerging nanodelivery systems for cuproptosis induction: design strategies and multidimensional regulatory mechanisms.

PMID: 41483832 · 2026

JournalInternational journal of pharmaceutics
Year2026
PMID41483832

Abstract

Cuproptosis, a newly discovered copper-dependent cell death mechanism, has emerged as a research hotspot in cancer therapy in recent years due to its unique metabolic intervention properties and profound interactions with the tumor microenvironment (TME). However, challenges persist in the precise delivery of cuproptosis-inducing agents, metabolic regulation, and synergistic integration with other treatment modalities. Here, we systematically review the latest advances in cuproptosis-based nanot

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.